ArticleGene therapy2002
Durable and stratum-specific gene expression in epidermis.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- A cellular disease model toward gene therapy ofMolecular therapy. Methods & clinical development · 2024Article
- Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.Vaccine · 2015Article
- Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms.Blood · 2012Article
- Transgenic mouse model expressing tdTomato under involucrin promoter as a tool for analysis of epidermal differentiation and wound healing.Transgenic research · 2012Article
- Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.Human gene therapy · 2012Article
- Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters.Gene therapy · 2010Article
- Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes.Experimental dermatology · 2005Article
- Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta.Journal of immunology (Baltimore, Md. : 1950) · 2004Article
- Vectors for the treatment of autoimmune disease.Gene therapy · 2003Review
- Adenoviral gene delivery to primary human cutaneous cells and burn wounds.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A number of genetic disorders are manifested in cutaneous epithelium and gene therapy approaches for treatment of such diseases are being considered. A successful gene therapy protocol requires durable and correctly targeted gene expression within the tissue. The continuous renewal and high levels of compartmentalization in epidermis are two challenges for a successful gene therapy of skin disorders. For those disorders which affect the upper layers of epidermis, vectors must be available that target stem cells, but remain silent until the progeny of these cells undergo differentiation. To explore the potential of long-term and targeted vector expression in epidermis, a hybrid retroviral vector encoding the reporter enhanced green fluorescent protein (EGFP) was constructed. The viral enhancer in the long terminal repeat of the vector was replaced with a 510-bp enhancer element of the human involucrin promoter. Keratinocyte-specific expression directed by the hybrid vector was demonstrated in culture and suprabasal-specific expression was observed in organotypic human epidermal cultures. In vivo transduction of mouse skin with this hybrid vector indicated long-term and stratum-specific expression of the transgene in mouse epidermis. The design of similar vectors for various gene therapy applications constitutes an important step toward clinically effective gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.